Manufacturing and Processing - Pharmaceutical Technology Asia Pacific
Apply for Free Subscription now!
Pharm Technology Europe Media Kit
Buyers Guide 2007/08
Get your free listing now!
Manufacturing and Processing
  • Why the future is in fragments?


    Using fragments, it is possible to exhaustively screen a target site to pick the best matching fragment for optimization.

    Managing the risks of PAT


    With operating efficiencies increasingly dependent on 'right first time', there is a need to change the status quo in the way processes are controlled.

    Characterizing amorphous materials with gravimetric vapour sorption techniques


    Amorphous materials in pharmaceutical formulations yield complex and challenging problems concerning the performance, processing and storage of these products.

    Catalyst screening


    The time-to-market constraints associated with modern drug development restricts the methodologies and reactions that can be used to make an API. In addition, there are also health and safety issues coupled with environmental factors to consider. An ideal reaction would use an innocuous catalyst to convert all of the substrate to the desired product. However, we are far from this ideal situation. A catalytic reaction has many advantages compared with one that uses a stoichiometric reagent: one molecule of catalyst can produce many molecules of product. This decreases the amount of reagent needed, which can have positive consequences for waste and cost.

    Achieving GLP compliance through deployment of LIMS


    A checklist of how to achieve regulatory compliance by validation of laboratory information management systems. Validation costs and cost-effective validation strategies are considered for pharmaceutical manufacturers to validate their systems and maintain a validated state for continued compliance.

    Avoiding pitfalls in scaling up biopharmaceutical production


    The scale-up of manufacturing processes to clinical production can be complicated and expensive, with many issues to consider. This article describes some of the common and less obvious pitfalls encountered by biopharmaceutical companies when scaling up protein production processes, and how to avoid them.

    Stacking the chips against counterfeits


    Is consolidated distribution the key to combating counterfeit drugs and parallel imports?

    Designing a winning process development strategy


    Improving productivity in downstream processing


    Improved feedstream titres are driving a demand for increased downstream processing productivity as manufacturers seek to lower the costs of monoclonal antibodies (MAbs). The unique selectivity of protein A has enabled platform technologies for MAb purification. Platform technologies and chromatography resin improvements can help manufacturers achieve rapid and economical process development and scale-up. A multiprong approach can enable downstream process scientists to enhance productivity.

18 November 2008
Search
Asia Pacific Biotech News
Asia Pacific Biotech News
Click here